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Abstract 
Background and Aim: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among women of 
reproductive age. The hypothalamus-pituitary-ovary axis dysregulates in PCOS, ultimately leading to 
hyperandrogenisms. Consequently, it is associated with hirsutism, dyslipidemia, obesity, infertility, menstrual 
disturbance, and insulin resistance. To our knowledge, there is no detailed investigation of these manifestations. That 
is why, this study aimed to evaluate manifestations of hyperandrogenism, hirsutism in particular. 
Methods: This study was performed on 39 women with an initial diagnosis of polycystic ovary syndrome. Rotterdam 
criteria including Oligo- or anovulation, hyperandrogenism clinical and/or biochemical signs, and ultrasound 
appearance of polycystic ovaries used as diagnostic criteria. Hirsutism scoring was carried out according to Freeman-
Gallwey’s definition of hirsutism. The patients were analyzed for other skin problems including male pattern baldness, 
acanthosis nigricans, and acne as well as demographic features.  
Results: Hirsutism was observed in the majority of our patients (91%) ranging from mild to severe. Concerning the 
distribution of hirsutism on various parts of the body, severe hirsutism was observed more on the groin, abdominal 
area, and chin respectively. Male pattern baldness, acanthosis nigricans, and acne, and dysregulated menstruation were 
reported in these patients.  
Conclusion: This investigation found that skin manifestations, especially hirsutism, are highly frequent in patients 
with PCOS. 
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Polycystic ovary syndrome (PCOS) is a serious 
health problem in women all around the world yet. 
PCOS is the most frequent endocrine disorder and 
ovarian malfunction in women and causes dozens 
of problems for those affected by (1). It affects 
around 6% to 20% of women of their reproductive 
age according to different diagnostic criteria (2).  
The PCOS is characterized by manifestations of 
excessive androgen secretion (hyperandrogenism) 
including ovulatory dysfunction, and polycystic 
morphology of ovaries (3, 4). It is asserted that 
underlying reasons for hyperandrogenism 
originated from infancy or embryonic stages of life 
(5). Irregular menses (oligomenorrhoea or 
amenorrhea) and hirsutism are also reported as 
common manifestations of PCOS. Moreover, the 
patients have a raised risk of having difficulty in 
pregnancy (2, 4). Besides, it is indicated that 
approximately 50 to 80% of patients suffer from 
obesity (6). Lower levels of high-density 
lipoprotein (HDL) cholesterol and higher levels of 
triglyceride and low-density lipoprotein (LDL) 
cholesterol in PCOS, in comparison with normal 
individuals, is also reported (7). Hirsutism is an 
abnormal cutaneous condition due to 
hyperandrogenism in which the male pattern of 
terminal hair growth occurs (2). It is indicated that 
approximately 60% of women with hirsutism are 
diagnosed as PCOS cases (8). Hirsutism scoring is 
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based on a modified Ferriman–Gallwey scoring 
chart (9). 
In the PCOS, the steroidogenesis rate in ovaries’ 
theca cells is higher than the normal condition 
which leads to its increased androgen secretion 
(10). It seems that this excessive androgen disrupts 
negative feedback of progesterone on gonadotropin-
releasing hormone (GnRH) pulse generator of 
hypothalamus due to androgen receptor blockers 
(11, 12). Rapid GnRH secretion causes higher 
luteinizing hormone (LH) secretion from the 
anterior pituitary and a relative decrease of the 
follicle-stimulating hormone. (FSH) Subsequently, 
the higher LH causes more steroidogenesis in theca 
cells of the ovaries and ultimately 
hyperandrogenemia in the PCOS (4, 11, 12). 
Moreover, resistance to insulin and subsequent 
hyperinsulinemia due to the intrinsic defect of 
insulin action is another challenge in these patients. 
Hyperinsulinemia increase androgen level through 
three different mechanisms: by increasing LH 
dependent androgen secretion from theca cells, by 
corticotropin dependent androgen secretion from 
adrenal and the last, reduction in hepatic production 
of SHBG and subsequent increase in bioavailable 
free testosterone (4, 13). Even though lots of 
investigation has been carried out on skin 
manifestations in PCOS, regard to our search on 
various databases such as PubMed and Google 
Scholar, we did not find any investigation 
conducting on the determination of Hirsutism and 
other related cutaneous manifestations in a detailed 
manner in patients with PCOS. They just reported 
general scoring of these manifestations in PCOS 
while this is indispensable to know the exact figures 
in every part of the body. This is why the current 
investigation sought to evaluate the manifestation of 
hyperandrogenism in patients with PCOS.  
Methods 
Thirty-nine women adults with an initial diagnosis 
of polycystic ovary syndrome in the age range of 20 
to 40 years (BMI≤ 30 kg/m2) were recruited at Dr. 
Mohmmadreza Mirzaei clinic located in Najafabad 
Azad University. Any patients under metformin or 
hormonal therapy over the previous three months 
were excluded. Moreover, the patients with 
pregnancy, thyroid dysfunction, neoplasms, 
prediabetes (including impaired glucose tolerance 
and impaired fasting glucose), diabetes, 
hypertension, liver diseases, and renal impairment 
(serum creatinine 120 mol/L) were excluded.   
Rotterdam criteria including Oligo- or anovulation, 
hyperandrogenism clinical and/or biochemical 
signs, and ultrasound appearance of polycystic 
ovaries with the exclusion of other etiologies 
(congenital adrenal hyperplasia, androgen-secreting 
tumors, Cushing’s syndrome) used as diagnostic 
criteria (14). By an endocrinologist, a validated 
questionnaire was filled for each patient. The 
questioner was asking for general demographic 
information (lifestyle, medication, and family 
history), medical history (like diabetes, 
hypertension, and dyslipidemia), and menstrual and 
fertility history. Ethical approval 
(IR.LAU.NAJAFABAD.REC.1394.14) was 
obtained from the committee of Islamic Azad 
University, Najafabad Branch, and signed consent 
obtained from each participant. The body mass 
index (BMI) of each patient was calculated with a 
standard formula. Hirsutism is the patients who 
were scored according to the Freeman-Gallwey 
definition (Table 1) (9). The patients were analyzed 
for other skin problems including male pattern 
baldness, acanthosis nigricans, and acne as well.  
 
Table 1. Freeman-Gallwey definition of hirsutism 






This investigation carried on 39 women with the 
age range of 20–40 years who had met the 
Rotterdam diagnostic criteria for PCOS.  
Demographic features and BMI:  
Demographic features were obtained by the 
questioner. Most of our patients were housewives 
(41%) and around one-third was a student and 
employed each. Around half of the cases were 
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married and had enough daily activity. The greater 
proportion of the patients had not got children and 
were not under any special diet (79.4%) (Table 2).  
After BMI calculation, it was found that great 
proportions of our patients is overweight (43.6%) 
and near half of them are normal. However, three 
patients were underweight (Table 3). 
 
Table 2. Demographic features of the study participants 











Child Has a child 
No child  
8 (~20.5%) 
31 (~79.4%) 
Diet No diet 
Under anti-obesity medicines 
Home diet  
31 (~79.4%) 







Table 3. BMI index status among the patients 
Status Frequency (n=39) 
Underweight (BMI<18 kg/m2) 3 (7.7) 
Normal weight (18 kg/m2<BMI<25 kg/m2) 19 (48.7) 
Overweight (25 kg/m2<BMI<29/9 kg/m2) 17 (43.6) 
 
Hyperandrogenism manifestations  
Hirsutism 
The study participants were analyzed for hirsutism 
in various regions of their bodies concerning 
Freeman-Gallwey criteria. It was found that the vast 
majority of the patients (40%) have moderate 
hirsutism. The figures for mild and normal 
hirsutism were found to be 31% and 20% 
respectively. Moreover, a small proportion of the 
patients (around 9%) had severe hirsutism (Figure 
1).  
Concerning the distribution of hirsutism on various 
parts of the body, severe hirsutism was observed 
more on the groin, abdominal area, and chin 
respectively. Moderate hirsutism was seen more on 
the chest additionally but less on the groin. The 
highest figures for mild hirsutism were recorded for 
the chin and chest. The lumbar area has the least 
hirsutism among our patients (Table 4). 
 
 
Figure 1. Hirsutism distribution in the patients 
according to the Freeman-Gallwey definition. Near 






Normal skin Mild hirsutism
Moderate hirsutism Severe hirsutism
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None of them 
n:39 (%) 
Behind the lips 6 (15.3) 7 (17.9) 8 (20.5) 18 (46) 
Chin 11(28.2) 10 (25.6) 9 (23) 9 (23) 
Chest 4 (10.2) 11 (28.2) 14 (35.8) 10 (25.6) 
Lumbar area 4 (10.2) 9 (23) 6 (15.3) 20 (51.2) 
Abdominal area 12 (30.7) 11(28.2) 7 (17.9) 9 (23) 
Groin 17 (43.5) 7 (17.9) 4 (10.2) 11 (28.2) 
Around the buttocks 7 (17.9) 7 (17.9) 5 (12.8) 20 (51.2) 
 
Table 5: hyperandrogenism clinical manifestation among the patients 
Manifestation  Frequency       n=39 (100.0%) 
Menstrual status Oligomenorrhea  
Amenorrhea 












Acanthosis nigricans  With acanthosis nigricans 
Without acanthosis nigricans 
27 (~69.23%) 
12 (~31.87%) 






Figure 2. Distribution of acne in the patients. Near 
half of the patients had acne on their face. 
 
Other manifestations:  
The patients had various patterns of menstruation. 
Around two-third had Oligomenorrhea and just two 
patients had Amenorrhea while 14 people (out of 
39) had regular menses. A considerable number of 
our patient does did not show cysts in sonography 
of their ovaries. Around half of them had male 
pattern baldness. Acanthosis nigricans and acne 
also were commonly observed in our patients 
(Table 5). Concerning the different parts of their 
body, face and groin were the most parts affected 
by acne and acanthosis nigricans respectively 
(Figures 2 and 3).  
 
 
Figure 3. Distribution of acanthosis nigricans in the 
patients, 46% of patients with acanthosis nigricans, 
manifested this disorder on their groin and 44% in 
the auxiliary region. 
Discussion 
Polycystic ovary syndrome is the most frequent 
endocrine disorder and ovarian malfunction in 










Auxiliary region Groin Neck
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ovarian interaction (1). Hyperandrogenism is a 
hallmark property of PCOS and causes clinical 
manifestation like hirsutism, acne, alopecia, and 
menstrual cycle disturbances (15). This 
investigation was aimed to evaluate 
hyperandrogenism manifestation in women with 
PCOS.  
A vast majority (approximately 60%) of our 
patients had oligomenorrhea while amenorrhea was 
recorded in only two cases. Besides, 36% were 
without menstrual disturbance. This result does not 
corporate with Ovalle et al. who have reported that 
15% and 50% of their patients have oligomenorrhea 
and amenorrhea respectively (16). In an 
investigation on 1297 women with PCOS, was 
indicated that regulated menstruation progressively 
raised by aging. Moreover, they found menstrual 
cycle disturbance is more observed in “classic” 
PCOS phenotypes (anovulation, 
hyperandrogenemia, and polycystic ovaries (17).  
It is claimed that hirsutism is considered as a main 
clinical marker of hyperandrogenisms in all PCOS 
guidelines, that is why it is one of the diagnostic 
criteria (18-21). Concerning our results, 91% of our 
patients had hirsutism, ranging from mild to severe. 
This result agrees with previous studies that report 
hirsutism as a common (65-75%) cutaneous 
manifestation of PCOS (22-24). However, it is 
asserted that some PCOS cases may have not 
cutaneous manifestation despite their elevated 
androgen levels or may have acne and/or hair loss 
without significant hirsutism (19). It seems not only 
hirsutism affected by circulating androgen level but 
it is also influenced by local androgen and growth 
factors concentrations and follicles’ androgen 
sensitivity (19). Our findings showed that various 
parts of the body have different hirsutism scores. 
The reason may lie in the aforementioned variables. 
Acne which is another common cutaneous 
manifestation of PCOS, found in 66.7% of the 
patients. However, it is claimed that the prevalence 
of acne in PCOS could alter ethnic composition 
(19). Around 33% of our patients had not ovarian 
cysts. Concerning previous studies, PCOS women 
may have not ovarian cysts or a woman with cyst 
might not be PCOS cases (25).  
Conclusion 
In conclusion, polycystic ovary syndrome is still a 
great concern for women of reproductive age all 
around the world. Hirsutism, a hyperandrogenism’s 
clinical sequela, is one of the most frequent 
coetaneous manifestations among the patients. The 
current study finds that skin problems like hirsutism 
are frequent among these patients. 
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